FIGURE 2.

The diagnostic and prognostic biomarker for CASH developed by traditional statistics, and validated by ML methods. A, The canonical values estimated with the diagnostic CASH biomarker (−3.37*[sCD14] + 1.47*[ C-Reactive Protein] – 0.36*[vascular endothelial growth factor [VEGF] – 0.57*[ interleukin [IL]-10]) were 6-fold greater in subjects who experienced a SH in the year prior to plasma sample collection (P < .001). The diagnostic CASH biomarker was able to distinguish prior CASH patients with a sensitivity of 80% and specificity of 77%. B, The canonical values calculated using the prognostic CASH biomarker (−0.135*[sCD14] + 7.73*[IL-1β] − 0.775*[VEGF] + 0.658*[sROBO4]) were 5-fold higher (P < .001) in cases who experienced a SH in the year following the plasma sampling. The prognostic CASH biomarker was able to distinguish patients with 86% sensitivity and 88% specificity. ***P < .001